title: Fexofenadine in pediatrics: oral tablet and suspension formulations.
abstract: Allergic rhinitis is a common chronic condition in children. Oral antihistamines are a first-line treatment option in allergic rhinitis and different formulations are available to aid administration to children. The tablet formulation of the second-generation antihistamine fexofenadine has established efficacy and safety in both adults and children. To aid administration in young children, a new oral suspension formulation of fexofenadine has been developed, indicated for the relief of seasonal allergic rhinitis symptoms in children aged 2-11 years and for uncomplicated skin manifestations of chronic idiopathic urticaria in children aged 6 months-11 years. Clinical studies have shown the oral suspension to have both bioequivalence with the 30 mg tablet formulation and a favorable safety and tolerability profile.
authors.affiliation: Texas Tech Regional Health Science Center, 1901 Arizona Avenue, El Paso, Texas 79902, USA. immunman@pol.net
authors.forename: Lyndon E
authors.initials: LE
authors.lastname: Mansfield
mesh_terms: D000284:Administration, Oral; D000818:Animals; D002626:Chemistry, Pharmaceutical; D002648:Child; D002675:Child, Preschool; D003679:Deglutition / Q000502:physiology; D006801:Humans; D007223:Infant; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy / Q000453:epidemiology; D013535:Suspensions; D013607:Tablets; D016593:Terfenadine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry
chemical_list: D013535:Suspensions; D013607:Tablets; D016593:Terfenadine; C093230:fexofenadine